

Agenda

- *Professor Grant McArthur* **MMP Update**
- *Hayley Andersen* **Presentation of MPA National Melanoma Award to MMP**
- *Associate Professor John Kelly* **In Situ Melanoma: How does melanoma start and how do we find it before it can spread?** (30 min)
- *Professor Jonathan Cebon* **Liquid biopsy BRAF testing at the ONJCRI** (10 min)

Research Vignettes

- *Paul White* – Consumers and MMP;
- *Andreas Behren* - Interactions between the immune-system and primary melanoma;
- *Lorey Smith* – Investigating melanoma’s sweet tooth
- *Katherine Woods* - T cell targeting of melanoma;
- *Nikki Adler* - Metastatic pathways in patients with cutaneous melanoma
- *Annie Wong* - Melanoma Immunotherapy Biomarkers: Finding the Right Treatment for the Right Patient



“Melbourne Melanoma Project- Achievements of 2016”

- Major contribution of MMP to the American Joint Cancer Committee Staging System
- First accredited “liquid biopsy” test for BRAF
- New strategic direction in early phase clinical trials
- Name change to come
- New opportunities for funding



“Melbourne Melanoma Project-Metrics”

In September 2016.....


MMP Cohort

- 2144 participants
- 700 primary melanoma FFPE blocks
- 955 participants with blood samples
- 11367 vials plasma
- 9793 vials serum
- 4472 vials blood pellets

99% of participants have been included in one or more research projects



MMP Projects



D = clinical data; B = biospecimen



MMP Publications




113 MMP affiliated publications to date

↑ number of publications per year

↑ number of MMP **collaboration** publications



“Major contribution of MMP to the American Joint Cancer Committee Staging System”




**“Major contribution of MMP to the American
Joint Cancer Committee Staging System”**

**“The Melbourne Melanoma Project
has contributed data from *1409*
participants to revision of the
staging system (8th edition)”**

Thank you!

Melanoma - stage defines treatment



Towards “Next-Gen”


Molecular Classification & Staging in Melanoma

- Significant prognostic/predictive capacity driven principally by *clinicopathological* evidence-based risk-stratification
- Tremendous strides in our understanding of the molecular/immunologic underpinnings and heterogeneity of melanoma

“First accredited “liquid biopsy” test for BRAF”




“New strategic direction in early phase clinical trials”



“Name change to come”

Melanoma Research Victoria



“New opportunities for funding -\$500,000 per annum”

- Government
 - Victorian Cancer Agency
 - Victorian Department of Health
 - Medical Research Future Fund
- University Sector
 - University of Melbourne
 - Monash University
 - Latrobe University
- Philanthropy
 - Foundations
 - Direct
- Industry
 - Health Data
 - Pharmaceutical Industry



Acknowledgements



Peter Mac

Peter MacCallum Cancer Centre
Victoria Australia



**Olivia
Newton-John**

Cancer Wellness & Research Centre



**Victorian
Cancer
Agency**

Linking research and patient care

BORDER MEDICAL

ONCOLOGY



**Victorian
Cancer
Biobank**

Kathleen
Cunningham
Foundation

kConFab

CONsortium for
research into
FAMILIAL Breast Cancer

The Melbourne Melanoma Project is supported by the Victorian Government through a Victorian Cancer Agency Translational Research Project grant.



**MELBOURNE
MELANOMA
PROJECT**